Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates

分组1 - Tango Therapeutics reported a quarterly loss of $0.35 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.24 per share a year ago [1] - The company's revenues for the quarter ended June 2025 were $3.18 million, missing the Zacks Consensus Estimate by 48.58%, and down from $19.88 million year-over-year [2] - Over the last four quarters, Tango Therapeutics has surpassed consensus EPS estimates only once [1][2] 分组2 - The stock has increased approximately 113.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $6.27 million, and for the current fiscal year, it is -$1.36 on revenues of $25.37 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]